$ASND News
Last published 1d ago
- 1d agoASNDAscendis Pharma to Participate in the Jefferies London Healthcare ConferenceGlobeNewswireCOPENHAGEN, Denmark, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 17, 2026, at 11:30 a.m. Greenwich Mean Time (GMT) / 6:30 a.m. Eastern Time / 3:30 a.m. Pacific Time in London, United Kingdom.
- 5d agoASNDOnce-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European UnionGlobeNewswire– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Orphan Medicinal Products
- 5d agoASNDOnce-Weekly TransCon® CNP (Navepegritide) to Receive 10 Years of Market Exclusivity Upon Approval in the European UnionGlobeNewswire– Final European Commission decision expected during Q4 2026 COPENHAGEN, Denmark, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND)...
- 6d agoASNDAscendis to Report Third Quarter 2026 Financial Results and Provide Business Update on November 12, 2026GlobeNewswireCOPENHAGEN, Denmark, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report third quarter 2026 financial results and provide a business update on Thursday, November 12,
- 2w agoASNDTransCon® PTH (Palopegteriparatide) Demonstrates Sustained, Clinically Meaningful Improvements in Kidney Function in Adults with Hypoparathyroidism Treated Up to 5 YearsGlobeNewswireCOPENHAGEN, Denmark, Oct. 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data demonstrating early, sustained, and clinically meaningful improvements in kidney function in adults
- 3w agoASNDOnce-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in ChildrenGlobeNewswireCOPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has
- 1mo agoASNDAscendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026GlobeNewswireCOPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR
- 1mo agoASNDAscendis Pharma - 1774519 - ASCENDIS PHARMA AEarnings Call TranscriptsHello, everyone. I'm Max Skor, a biotech analyst with Morgan Stanley. Welcome. And just to start off, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com forward
- 1mo agoASNDAscendis Pharma - 1774519 - ASCENDIS PHARMA AEarnings Call TranscriptsHello, everyone. I'm Max Skor, a biotech analyst with Morgan Stanley. Welcome. And just to start off, for important disclosures, please see the Morgan Stanley Research Disclosure website at www.morganstanley.com forward
- 1mo agoASNDAscendis to Regain Rights to TransCon® Technology in Metabolic and Cardiovascular DiseasesGlobeNewswire- All rights to TransCon technology-based products in metabolic and cardiovascular diseases, including once-monthly TransCon Semaglutide, will revert to Ascendis- Ascendis to initiate multiple programs in metabolic and
- 1mo agoASNDAscendis Announces Planned $400 Million Share Repurchase ProgramGlobeNewswireCOPENHAGEN, Denmark, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its Board of Directors has authorized the Company to repurchase up to $400 million of the Company’s
- 2mo agoASNDFirst Infant Data from Ascendis Trial of Once-Weekly TransCon CNP (Navepegritide) Presented at ESPE 2026GlobeNewswire– Achondroplasia Foramen Magnum Score was stable or improved between baseline and Week 52 with TransCon CNP treatment – Treatment with TransCon CNP increased linear growth in the sentinel cohort, with an improvement
- 2mo agoASNDAscendis Pharma to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceGlobeNewswireCOPENHAGEN, Denmark, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare
- 2mo agoASNDAscendis to Share Its Latest Endocrinology Rare Disease Data at ESPE 2026GlobeNewswireCOPENHAGEN, Denmark, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it will share the latest data from its Endocrinology Rare Disease programs during ESPE 2026, the annual
- 2mo agoASNDAscendis and BioMarin Enter Binding Term Sheet for a Global Settlement and License Agreement Related to YUVIWEL® (Navepegritide)GlobeNewswireCOPENHAGEN, Denmark, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has entered into a binding term sheet for a global settlement and license agreement with BioMarin
- 2mo agoASNDAscendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026GlobeNewswireCOPENHAGEN, Denmark, Aug. 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its participation at ISDS 2026, the annual meeting of the International Skeletal Dysplasia Society being
- 2mo agoASNDEyconis Announces Initiation of First-in-Human Clinical Trial of EYC-0305 in Treatment-Naïve Wet Age-Related Macular Degeneration PatientsGlobeNewswireFirst patients dosed in OVERTURE, a Phase 1b/2a study evaluating EYC-0305, a potential long-acting anti-VEGF therapy designed for six-month or longer dosing intervals via standard intravitreal injection Milestone marks
- 3mo agoASNDQ2 2026 Ascendis Pharma Earnings Conference Call - ASCENDIS PHARMA AEarnings Call TranscriptsLadies and gentlemen, thank you for standing by. Welcome to the second quarter 2026 Ascendus Pharma earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, th
- 3mo agoASNDAscendis Pharma Reports Second Quarter 2026 Financial ResultsGlobeNewswire– Q2 2026 product revenue of €315 million (+105% Y/Y), comprising €252 million for YORVIPATH®, €55 million for SKYTROFA®, and €8 million for YUVIWEL® – Through July 31, more than 220 unique YUVIWEL patient
- 3mo agoASNDAscendis to Report Second Quarter 2026 Financial Results and Provide Business Update on August 13, 2026GlobeNewswireCOPENHAGEN, Denmark, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report second quarter 2026 financial results and provide a business update on Thursday, August 13,
- 3mo agoASNDAscendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S.GlobeNewswireTransCon® CNP and TransCon hGH combination therapy Week 78 data from the Phase 2 COACH Trial showed durable, unprecedented increase in healthy, proportional growthTransCon CNP monotherapy Week 104 data from the pivotal
- 4mo agoASNDChildren with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH TrialGlobeNewswireData presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104Greater improvements observed in children with preexisting genu
- 4mo agoASNDAscendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®GlobeNewswireCOPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the
- 5mo agoASNDPhase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with HypoparathyroidismGlobeNewswireMulti-organ system and quality-of-life benefits sustained through three and a half years 86% response rate for the multi-component endpoint 89% of patients completed the three-and-a-half-year trial COPENHAGEN, Denmark,
- 5mo agoASND5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with HypoparathyroidismGlobeNewswire– Multi-organ system and quality-of-life benefits sustained through five years of treatment – 82% response rate for the multi-component endpoint – 95% of patients completed five years of treatment COPENHAGEN,
- 5mo agoASNDAscendis to Showcase Advances in Treatment of Rare Endocrine Diseases at ENDO 2026GlobeNewswireCOPENHAGEN, Denmark, June 08, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its Endocrinology Rare Disease programs in hypoparathyroidism, achondroplasia, and
- 6mo agoASNDAscendis Pharma Reports First Quarter 2026 Financial ResultsGlobeNewswire- Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments
- 6mo agoASNDNew 2-Year Data from Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) Show Pronounced Gains in Growth Outcomes in Children with Achondroplasia Aged ≥5 YearsGlobeNewswireCOPENHAGEN, Denmark, May 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from a subgroup analysis showing that children with achondroplasia ≥5 years of age at enrollment treated
- 6mo agoASNDAscendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026GlobeNewswireCOPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026,
- 6mo agoASNDAscendis Announces Redemption of All $575 Million of Outstanding 2.25% Convertible Senior Notes Due 2028GlobeNewswireCOPENHAGEN, Denmark, April 21, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that it has called all $575.0 million aggregate principal amount of its outstanding 2.25% Convertible Senior
- 6mo agoASNDAscendis Pharma Announces Commencement of Trading of its Ordinary Shares on NasdaqGlobeNewswireCOPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the
- 7mo agoASNDAscendis Pharma to List Ordinary Shares Directly on NasdaqGlobeNewswire- Ordinary shares expected to commence trading on Nasdaq on April 20, 2026 following exchange of all American Depositary Shares (ADSs) - ADS holders will receive one ordinary share listed on Nasdaq for each ADS held
- 7mo agoASNDNew Data from Week 52 of the Ongoing COACH Trial Showed that TransCon® hGH Accelerated TransCon® CNP's Benefits Beyond Linear Growth in Children with AchondroplasiaGlobeNewswire- Unprecedented improvements in arm span observed with TransCon CNP and TransCon hGH combination therapy, a measure highly meaningful to the achondroplasia community - Enhanced improvements in spinal canal dimensions
- 7mo agoASNDAscendis Receives Orphan Drug Exclusivity and Launches YUVIWEL® (Navepegritide) in the United StatesGlobeNewswire- YUVIWEL was granted orphan drug exclusivity by U.S. FDA to increase linear growth in pediatric patients 2 years of age and older with achondroplasia with open epiphyses - YUVIWEL is now commercially available in the
- 8mo agoASNDNew Two-Year Data from Pivotal ApproaCH Trial Showing Durable Benefits of TransCon® CNP (Navepegritide) in Children with Achondroplasia Shared at ACMG 2026GlobeNewswireCOPENHAGEN, Denmark, March 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new data from its pivotal ApproaCH Trial showing that children with achondroplasia treated with once-weekly
- 8mo agoASNDAscendis Pharma to Participate in the TD Cowen 46th Annual Health Care ConferenceGlobeNewswireCOPENHAGEN, Denmark, March 02, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in a virtual fireside chat at the TD Cowen 46th Annual Health Care
- 8mo agoASNDFDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and OlderGlobeNewswireThe first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease
- 9mo agoASNDAscendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial ResultsGlobeNewswireQ4 2025 product revenue of €240 million and FY 2025 product revenue of €684 millionQ4 2025 operating profit of €10 million and cash flow from operating activities of €73 millionTransCon® CNP under FDA Priority
- 9mo agoASNDAscendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026GlobeNewswireCOPENHAGEN, Denmark, Feb. 04, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report full year 2025 financial results and provide a business update on Wednesday, February 11,
- 10mo agoASNDAscendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCOPENHAGEN, Denmark, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today provided a business and strategic roadmap update, including planned 2026 key corporate milestones. Ascendis President and
- 10mo agoASNDWeek 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH)GlobeNewswire– Once-weekly TransCon® CNP and TransCon® hGH combination therapy showed durable growth without compromising safety or tolerability at 52 weeks – Annualized growth velocity (AGV) exceeded the 97th-percentile
- 10mo agoASNDAscendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceGlobeNewswireCOPENHAGEN, Denmark, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that company executives will participate in the 44th Annual J.P. Morgan Healthcare Conference and provide a
- 11mo agoASNDAscendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with AchondroplasiaGlobeNewswire– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to February 28, 2026 COPENHAGEN, Denmark, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the
- 11mo agoASNDResults of Pivotal ApproaCH Trial of TransCon® CNP (Navepegritide) in Children with Achondroplasia Published in JAMA PediatricsGlobeNewswireCOPENHAGEN, Denmark, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that pivotal Week 52 results from its randomized double-blind, placebo-controlled ApproaCH Trial of
- 12mo agoASNDAscendis Pharma Reports Third Quarter 2025 Financial ResultsGlobeNewswire– Q3 2025 revenue of €143.1 million for YORVIPATH® and €50.7 million for SKYTROFA® – Q3 2025 operating profit of €11.0 million – TransCon® CNP (navepegritide) under FDA Priority Review for the
- 1y agoASNDNew Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon® PTH (Palopegteriparatide)-Treated Adults with HypoparathyroidismGlobeNewswireCOPENHAGEN, Denmark, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that a new pooled analysis showed sustained and clinically meaningful improvements in renal function in adults
- 1y agoASNDAscendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025GlobeNewswireCOPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12,
- 1y agoASND3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon® PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025GlobeNewswireCOPENHAGEN, Denmark, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that its data showing sustained improvements in renal function, continued normalization of urine calcium
- 1y agoASNDAscendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon® CNP for Treatment of Children with AchondroplasiaGlobeNewswireCOPENHAGEN, Denmark, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for TransCon
- 1y agoASNDAscendis Pharma Bone Diseases A/S - Appeal, AffirmedUS Patent Trial and Appeal Board